CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Thymostimulin versus placebo for treatment of advanced hepatocellular carcinoma: A randomized, controlled, double-blind, multicenter study
DOI 10.1055/s-0028-1089473
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMM Dollinger, C Lautenschläger, J Lesske, WE Fleig
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials. The aim of this study was to assess its efficacy in a phase III trial. Methods: Patients (age 18 to 75 years) with biopsy-proven HCC not amenable to or failing local and surgical therapy were randomized to receiv…
Zitieren
Zitierempfehlung
MM Dollinger, C Lautenschläger, J Lesske, WE Fleig (2008) Thymostimulin versus placebo for treatment of advanced hepatocellular carcinoma: A randomized, controlled, double-blind, multicenter study. Zeitschrift für Gastroenterologie (09). https://doi.org/10.1055/s-0028-1089473
Mit CareLit weiterarbeiten